Needham & Company Reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS); Pipelines to Address Cancer Through Antisense Technology
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' rating on ISIS Pharmaceuticals (Nasdaq: ISIS), PT $22.
Needham analyst says, "In the near-term ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "In the near-term ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
